Target intelligence / Profile preview

WD repeat domain 93 (WDR93)

Target
WDR93
Molecular classification
WD40 repeat protein, Protein component of respiratory chain complex I, Scaffold protein, Oxidoreductase
01

Overview

WD repeat domain 93 (WDR93) encodes a protein that contains WD40 repeats, which are short structural motifs forming a β-propeller scaffold. This specific protein is predicted to be a component of mitochondrial respiratory chain complex I, the first enzyme of the electron transport chain responsible for NADH oxidation and ATP production. Proteins containing WD40 repeats are highly conserved and versatile, typically involved in organizing multi-protein complexes and mediating protein-protein interactions in essential cellular processes, including but not limited to signal transduction, transcription regulation, and apoptosis. Mutations or defects in the components of complex I can contribute to mitochondrial disease and have been genetically associated with some forms of primary biliary cirrhosis. Direct targeting of WDR93 is not prevalent in current pharmacology, but the WD-repeat family is being explored as a novel target class for intervention in diseases involving protein complex dysfunction.

Other names
WD repeat domain 93WDR93HGNC:26924NCBI Gene:56964Ensembl:ENSG00000140527OMIM®:619891UniProtKB/Swiss-Prot:Q6P2C0GC15P088036GC15P090234GC15P066346
02

Mechanism of action

For drugs that affect complex I: inhibition of electron transfer and ATP production (not specific to WDR93, but general to complex I inhibitors)

03

Biological functions

Electron transport chainRespiratory chain functionMitochondrial energy metabolism
04

Disease associations

Primary biliary cirrhosis, type 3 and 5 (genetic association)Not widely implicated in cancer, cardiovascular, neurodegenerative, or inflammation so far.
05

Safety considerations

General risks related to complex I inhibition: mitochondrial dysfunction, lactic acidosis, and cytotoxicity.Targeting WDR93 specifically is uncharacterized and may disrupt energy metabolism
06

Interacting drugs

None specifically documented for WDR93 in current databases; proteins of complex I are generally affected by inhibitors like rotenone and metformin, but direct WDR93-targeting drugs are not described
07

Biomarkers

None specifically documented for WDR93; respiratory chain complex I defects may serve as general biomarkers for mitochondrial diseases.

Beyond the preview

Go deeper on WD repeat domain 93 (WDR93).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD repeat domain 93 (WDR93).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call